Article
Critical Care Medicine
Yosafe Wakwaya, Deepa Ramdurai, Jeffrey J. Swigris
Summary: Chronic cough in patients with IPF may involve multiple mechanisms, including comorbid conditions and IPF itself. Diagnostic and management approaches need to be multi-faceted, but may lack robust data support.
Article
Multidisciplinary Sciences
Aahd Kubbara, William H. Amundson, Adam Herman, Adam M. Lee, Jeffrey R. Bishop, Hyun Joo Kim
Summary: This study investigated the impact of genetic variations on the response and outcomes of pirfenidone treatment for IPF. It found that certain genetic variants were associated with improved survival and treatment response in IPF patients receiving pirfenidone.
Review
Biochemistry & Molecular Biology
Roxana-Elena Cirjaliu, Mariana Deacu, Ioana Gherghisan, Angela Stefania Marghescu, Manuela Enciu, Gabriela Izabela Baltatescu, Antonela Anca Nicolau, Doina-Ecaterina Tofolean, Oana Cristina Arghir, Ariadna-Petronela Fildan
Summary: This review provides a comprehensive analysis of the risk factors, clinical, radiologic, and histological features of both post-COVID-19 pulmonary fibrosis (PCPF) and idiopathic pulmonary fibrosis (IPF). It highlights the similarities and differences between these two diseases by gathering relevant articles published in English up until October 2022 using multiple databases. This review aims to assist clinicians, pathologists, and researchers in making accurate diagnoses and selecting patients for anti-fibrotic therapies and future therapeutic perspectives.
Review
Medicine, General & Internal
Alba Mulet, Jaime Signes-Costa
Summary: Idiopathic pulmonary fibrosis is a lung disease with unknown causes, which has a poor prognosis. Telomeric shortening may play an important role in its pathogenesis, but mutations in telomere-related genes are not always present. Telomere shortening can serve as a biomarker for disease prognosis independently of other clinical factors.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Pharmacology & Pharmacy
Xudan Yang, Zhihao Xu, Songhua Hu, Juan Shen
Summary: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease without a known cause. Current approved drugs for IPF, such as Pirfenidone and Nintedanib, can slow down the decline in lung function and reduce the risk of acute worsening. However, they cannot alleviate symptoms or improve overall survival. The development of new, safe, and effective drugs is necessary. Previous studies have shown that cyclic nucleotides and phosphodiesterase inhibitors may be potential targets for treating pulmonary fibrosis. This paper reviews the progress in research on PDE inhibitors and provides insights for the development of anti-pulmonary fibrosis drugs.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Claudia De Vitis, Michela D'Ascanio, Andrea Sacconi, Dario Pizzirusso, Valentina Salvati, Massimiliano Mancini, Giorgia Scafetta, Roberto Cirombella, Francesca Ascenzi, Sara Bruschini, Antonella Esposito, Silvia Castelli, Claudia Salvucci, Leonardo Teodonio, Bruno Sposato, Angela Catizone, Arianna Di Napoli, Andrea Vecchione, Gennaro Ciliberto, Salvatore Sciacchitano, Alberto Ricci, Rita Mancini
Summary: The study revealed that the B4GALT1 gene is overexpressed in IPF patients and human cell cultures, indicating it could serve as a potential novel marker for this disease.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Pharmacology & Pharmacy
Chengsheng Yin, Huikang Xie, Xian He, Yuan Zhang, Aihong Zhang, Huiping Li
Summary: This study aimed to investigate the occurrence of small airway dysfunction (SAD) comorbidity in idiopathic pulmonary fibrosis (IPF) and its impact on survival. The study found that 34.57% of IPF patients were diagnosed with SAD, and comorbid SAD was an independent risk factor for mortality in IPF patients.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Medicine, General & Internal
Theodoros Karampitsakos, Brenda M. Juan-Guardela, Argyris Tzouvelekis, Jose D. Herazo-Maya
Summary: Idiopathic pulmonary fibrosis (IPF) is a highly heterogeneous and lethal chronic lung disease. Precision medicine approaches have not been effectively implemented in IPF clinical practice, despite the existence of numerous diagnostic, prognostic, and theragnostic biomarker candidates.
Review
Biochemistry & Molecular Biology
Sheiphali Gandhi, Roberto Tonelli, Margaret Murray, Anna Valeria Samarelli, Paolo Spagnolo
Summary: Idiopathic pulmonary fibrosis (IPF) is a common and severe disease that primarily affects middle-aged and elderly males. In addition to aging, occupational and environmental exposures, as well as lifestyle factors such as smoking and diet, have been associated with an increased risk of IPF. Trigger factors may also lead to acute exacerbations and poor prognosis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Biochemistry & Molecular Biology
Hamid Mattoo, Shiv Pillai
Summary: This review focuses on the pathogenesis of fibrotic diseases, mainly looking at triggers, progression processes, therapies, and therapeutic trials. It primarily discusses idiopathic pulmonary fibrosis and systemic sclerosis, highlighting the contributions of inflammatory mechanisms and adaptive immunity respectively.
CELLULAR AND MOLECULAR LIFE SCIENCES
(2021)
Review
Pharmacology & Pharmacy
Qianru Mei, Zhe Liu, He Zuo, Zhenhua Yang, Jing Qu
Summary: Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease with limited understanding of its pathogenesis. Recent studies suggest that sustained lung epithelial injury and fibroblast differentiation play key roles in the development of IPF. Current treatments can slow disease progression but cannot cure it.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Pharmacology & Pharmacy
Mingyao Sun, Yangyang Sun, Ziru Feng, Xinliang Kang, Weijie Yang, Yongan Wang, Yuan Luo
Summary: IPF is a progressive disease characterized by an inexorable decline in lung function, involving multiple positive feedback loops and the crucial role of the Hippo/YAP signaling pathway. YAP/TAZ plays a key role in pulmonary fibrosis and alveolar regeneration by regulating cell proliferation and extracellular matrix deposition through different signaling pathways.
PHARMACOLOGICAL RESEARCH
(2021)
Review
Biochemistry & Molecular Biology
Paschalis Ntolios, Vassilios Tzilas, Evangelos Bouros, Eleni Avdoula, Ioannis Karakasiliotis, Demosthenes Bouros, Paschalis Steiropoulos
Summary: The interest in the lung microbiome and virome and their contribution to the pathogenesis of idiopathic pulmonary fibrosis (IPF) has been increasing. Higher microbial burden is associated with worse prognosis but no specific microbe has been identified to contribute to this. Infection is considered a cause of acute exacerbation of IPF, but the association of viral infection with AE-IPF has not been established.
Review
Cell Biology
Shengnan Yang, Peipei Liu, Yale Jiang, Zai Wang, Huaping Dai, Chen Wang
Summary: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with unknown causes, and currently the only medications that can slow down the progression of the disease and improve survival rate are pirfenidone and nintedanib. The use of mesenchymal stem cells (MSCs) provides a new hope for treating interstitial lung disease, but optimal treatment protocols are still lacking.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Respiratory System
Andrew Shapanis, Mark G. Jones, James Schofield, Paul Skipp
Summary: A machine learning model and multiple datasets were used to accurately predict idiopathic pulmonary fibrosis (IPF) and identified distinct subphenotypes of the disease.
Article
Cardiac & Cardiovascular Systems
Charlotte H. So, Mark H. Eckman
JOURNAL OF THROMBOSIS AND THROMBOLYSIS
(2017)
Article
Gastroenterology & Hepatology
Daniel E. Abbott, Ching Wei D. Tzeng, Matthew T. McMillan, Mark P. Callery, Tara S. Kent, John D. Christein, Stephen W. Behrman, Daniel P. Schauer, Dennis J. Hanseman, Mark H. Eckman, Charles M. Vollmer
Article
Cardiac & Cardiovascular Systems
Mark H. Eckman, Alexandru Costea, Mehran Attari, Jitender Munjal, Ruth E. Wise, Carol Knochelmann, Matthew L. Flaherty, Pete Baker, Robert Ireton, Brett M. Harnett, Anthony C. Leonard, Dylan Steen, Adam Rose, John Kues
AMERICAN HEART JOURNAL
(2018)
Editorial Material
Medicine, General & Internal
M. H. Eckman, E. S. Woodle, C. V. Thakar, F. Paterno, K. E. Sherman
ANNALS OF INTERNAL MEDICINE
(2018)
Article
Medicine, General & Internal
Mark H. Eckman, E. Steve Woodle, Charuhas V. Thakar, Flavio Paterno, Kenneth E. Sherman
ANNALS OF INTERNAL MEDICINE
(2018)
Article
Anesthesiology
Vidya Chidambaran, Rajeev Subramanyam, Lili Ding, Senthilkumar Sadhasivam, Kristie Geisler, Bobbie Stubbeman, Peter Sturm, Viral Jain, Mark H. Eckman
PEDIATRIC ANESTHESIA
(2018)
Article
Emergency Medicine
Justin L. Benoit, Pooja Khatri, Opeolu M. Adeoye, Joseph P. Broderick, Jason T. McMullan, Jan F. Scheitz, Achala S. Vagal, Mark H. Eckman
PREHOSPITAL EMERGENCY CARE
(2018)
Article
Cardiac & Cardiovascular Systems
Mark H. Eckman, Ruth Wise, Carol Knochelmann, Rachael Mardis, Sharon Wright, Ashish Gummadi, Estrelita Dixon, Richard Becker, Daniel P. Schauer, Matthew L. Flaherty, Alexandru Costea, Dawn Kleindorfer, Rob Ireton, Pete Baker, Brett M. Harnett, Adeboye Adejare, Anthony C. Leonard, Heidi Sucharew, Amy Costanzo, Lora Arduser, John Kues
Summary: This study aims to improve the level of anticoagulation therapy for patients with AF in our health system by implementing and evaluating the effectiveness of an Atrial Fibrillation Decision Support Tool (AFDST) embedded within our electronic health record.
AMERICAN HEART JOURNAL
(2022)
Review
Health Care Sciences & Services
Brittany Humphries, Montserrat Leon-Garcia, Ena Nino de Guzman Quispe, Carlos Canelo-Aybar, Claudia Valli, Kevin Pacheco-Barrios, Arnav Agarwal, Susan Mirabi, Mark H. Eckman, Gordon Guyatt, Shannon M. Bates, Pablo Alonso-Coello, Feng Xie
Summary: This study examined the use of decision analysis in shared decision making, finding that most studies concluded decision analysis was generally beneficial, but there was limited information on the implementation process. Rigorous randomized controlled trials are needed to confirm the effectiveness of these interventions, while qualitative studies should seek to understand their potential implementation.
JOURNAL OF CLINICAL EPIDEMIOLOGY
(2022)
Article
Medicine, General & Internal
Shuchi Gulati, Mark H. Eckman
Summary: Direct oral anticoagulants (DOACs) are a cost-effective and more effective alternative to low-molecular-weight heparin (LMWH) for treating cancer-associated thrombosis (CAT). The most cost-effective DOAC depends on the relative cost of each agent, making these findings important for treating physicians and health policymakers.
ANNALS OF INTERNAL MEDICINE
(2023)
Article
Health Care Sciences & Services
Adeboye A. Adejare, Heather J. Duncan, R. Geoffrey Motz, Silvi Shah, Charuhas Thakar, Mark H. Eckman
Summary: This study assessed the feasibility of using The Gambler II as a health utility assessment tool in an ambulatory dialysis clinic setting and explored the impact of race-matched versus race-mismatched exemplars on knowledge gained. The results showed that this approach was feasible and the educational information provided improved patients' knowledge and understanding of ESKD-related health states and the implications of organ transplantation with HCV-viremic kidneys.
JMIR FORMATIVE RESEARCH
(2022)
Article
Health Care Sciences & Services
Mark H. Eckman, Adeboye A. Adejare, Heather Duncan, E. Steve Woodle, Charuhas Thakar, Rita R. Alloway, Kenneth E. Sherman
Summary: The study explored the feasibility of sampling health utilities from hemodialysis patients to perform personalized decision analyses on transplantation strategies. Results showed wide variations in utilities for ESKD-related health states, with the highest mean value for transplantation with an HCV-uninfected kidney. Patient-specific decision analyses indicated that 37 out of 63 ESKD patients would benefit from transplantation of an HCV-viremic kidney.
MDM POLICY & PRACTICE
(2021)
Article
Health Care Sciences & Services
Mark H. Eckman, Margaret Powers-Fletcher, Jennifer W. Forrester, Carl J. Fichtenbaum, Richard Lofgren, Alan George Smulian
Summary: Vaccine hesitancy poses a challenge to widespread immunity against COVID-19. A decision model shows that both mRNA and adenovirus vector vaccines can yield similar outcomes in certain scenarios.
MDM POLICY & PRACTICE
(2021)
Article
Respiratory System
Nishant Gupta, Dale Langenderfer, Francis X. McCormack, Daniel P. Schauer, Mark H. Eckman
ANNALS OF THE AMERICAN THORACIC SOCIETY
(2017)
Article
Cardiac & Cardiovascular Systems
Mark H. Eckman, Alexandru Costea, Mehran Attari, Jitender Munjal, Ruth E. Wise, Carol Knochelmann, Matthew L. Flaherty, Pete Baker, Robert Ireton, Brett M. Harnett, Anthony C. Leonard, Dylan Steen, Adam Rose, John Kues
AMERICAN HEART JOURNAL
(2017)